Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Stock analysts at Edison Inv. Res issued their FY2025 EPS estimates for shares of Basilea Pharmaceutica in a research note issued to investors on Thursday, March 27th. Edison Inv. Res analyst J. Prakash anticipates that the company will earn $4.76 per share for the year.
Basilea Pharmaceutica Price Performance
Shares of BPMUF opened at $54.00 on Monday. The company has a current ratio of 4.10, a quick ratio of 3.27 and a debt-to-equity ratio of 5.70. The business’s fifty day moving average is $52.95 and its 200 day moving average is $52.64. Basilea Pharmaceutica has a 12-month low of $38.60 and a 12-month high of $54.00.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- How to Calculate Inflation Rate
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 03/24 – 03/28
- What is the Hang Seng index?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
